Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study

After SPN-820’s failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s therapy Onapgo to sustain the company.